Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High dosage haloperidol in chronic schizophrenia.

R G McCreadie, I M MacDonald

    The British Journal of Psychiatry : the Journal of Mental Science
    |September 1, 1977
    PubMed
    Summary

    High-dose haloperidol significantly improved chronic schizophrenic patients. Some patients maintained benefits on lower doses, with side effects resolving upon dose reduction or discontinuation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Mutations in PNPLA6 are linked to photoreceptor degeneration and various forms of childhood blindness.

    Nature communications·2015
    Same author

    Plasma lipid peroxide and serum vitamin E levels in subjects taking antipsychotic drugs.

    Journal of psychopharmacology (Oxford, England)·2012
    Same author

    An open study of remoxipride in the long-term treatment of schizophrenia-.

    Journal of psychopharmacology (Oxford, England)·2012
    Same author

    Tardive dyskinesia and deficit schizophrenia.

    Acta psychiatrica Scandinavica·2011
    Same author

    A founder mutation in BBS2 is responsible for Bardet-Biedl syndrome in the Hutterite population: utility of SNP arrays in genetically heterogeneous disorders.

    Clinical genetics·2010
    Same author

    Molecular modeling of retinoschisin with functional analysis of pathogenic mutations from human X-linked retinoschisis.

    Human molecular genetics·2010

    Area of Science:

    • Psychiatry
    • Clinical Pharmacology
    • Neuroscience

    Background:

    • Chronic 'drug-resistant' schizophrenia presents significant treatment challenges.
    • Long-term inpatient care settings require effective management strategies for persistent symptoms.

    Purpose of the Study:

    • To evaluate the efficacy and safety of high-dose haloperidol in chronic, drug-resistant male schizophrenic inpatients.
    • To assess the potential for dose reduction in maintaining treatment gains and managing side effects.

    Main Methods:

    • A double-blind, chlorpromazine-controlled trial was conducted over three months.
    • High-dose haloperidol (100 mg daily) was administered to male chronic schizophrenic inpatients.
    • A three-month follow-up assessed maintenance of improvement and side effect profiles.

    Main Results:

    • High-dose haloperidol demonstrated significant improvement in the mental state of participants.
    • Serious extrapyramidal side effects were not observed at high doses.
    • A majority of patients experienced behavioral deterioration (e.g., drowsiness) and elevated serum alkaline phosphatase levels.
    • These side effects resolved upon dose reduction or drug discontinuation during follow-up.

    Conclusions:

    • High-dose haloperidol can be effective for improving the mental state in chronic, drug-resistant schizophrenia.
    • Lower doses may maintain improvements, and side effects are manageable through dose adjustment or cessation.
    • Careful monitoring for behavioral changes and biochemical markers is warranted with high-dose haloperidol therapy.

    Related Experiment Videos